Answer
Jun 05, 2025 - 01:53 PM
OFEV (nintedanib) is a medication used to treat idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases with a progressive phenotype. Its success rate can vary depending on the condition being treated. Clinical trials have shown that OFEV can significantly slow the decline in lung function, as measured by forced vital capacity (FVC), in patients with IPF. However, the effectiveness and success rate can differ among individuals, and it is important for patients to discuss potential benefits and risks with their healthcare provider.
